Key Points
- United Therapeutics EVP Paul Mahon sold 8,300 shares on May 21 at an average price of $562.82, for proceeds of about $4.67 million. After the sale, he still owned 45,172 shares, reducing his stake by 15.52%.
- UTHR shares were trading slightly higher, opening at $565.87 and sitting near their 50-day moving average of $562.78. The stock is well above its 200-day moving average of $511.17 and near its 52-week high of $609.35.
- The company recently missed quarterly earnings expectations, reporting EPS of $5.82 versus the $7.00 consensus, while revenue also came in below estimates. Despite that miss, analysts remain generally positive, with a consensus rating of “Moderate Buy” and an average price target of $619.42.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the business's stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $562.82, for a total value of $4,671,406.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company's stock, valued at approximately $25,423,705.04. This trade represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
United Therapeutics Trading Up 0.3%
Shares of UTHR stock opened at $565.87 on Friday. The stock has a market cap of $24.02 billion, a P/E ratio of 20.89, a price-to-earnings-growth ratio of 1.82 and a beta of 0.60. The stock has a 50 day simple moving average of $562.78 and a 200 day simple moving average of $511.17. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the company earned $6.63 earnings per share. The firm's revenue for the quarter was down 1.6% on a year-over-year basis. Analysts forecast that United Therapeutics Corporation will post 27.07 EPS for the current year.
Analysts Set New Price Targets
Several equities research analysts have weighed in on the company. Cantor Fitzgerald upped their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an "overweight" rating in a research note on Thursday, March 12th. Raymond James Financial assumed coverage on United Therapeutics in a research note on Friday, April 10th. They set an "outperform" rating and a $700.00 target price for the company. Bank of America upped their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 31st. Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research note on Thursday, February 26th. Finally, Morgan Stanley set a $516.00 target price on United Therapeutics in a research note on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, United Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $619.42.
Read Our Latest Report on United Therapeutics
Institutional Trading of United Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of UTHR. Torren Management LLC acquired a new stake in United Therapeutics in the fourth quarter valued at $26,000. Activest Wealth Management increased its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC increased its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. increased its holdings in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC acquired a new stake in United Therapeutics in the fourth quarter valued at $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
